In a report released yesterday, Ross Osborn from Cantor Fitzgerald reiterated a Buy rating on Nyxoah (NYXH – Research Report), with a price target of $16.00. The company’s shares closed yesterday at ...
MedTech & Diagnostics Analyst Osborn, along with CMO Dr. Boon and Dr. Kaffenberger, Otolaryngologist, University of Pittsburgh Medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
